New topics in bradykinin research

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 66, Issue 11, 2011, Pages 1397-1406

  Maurer, M ^a   Bader, M ^b   Bas, M ^c   Bossi, F ^d   Cicardi, M ^e   Cugno, M ^f   Howarth, P ^g   Kaplan, A ^h   Kojda, G ⁱ   Leeb Lundberg, F ^j   Lotvall J ^k   Magerl, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF TRIESTE   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^j LUND UNIVERSITY   (Sweden)

^k UNIVERSITY OF GOTHENBURG   (Sweden)

more..

Author keywords

angioedema; bradykinin; C1 esterase inhibitor; icatibant

Indexed keywords

BRADYKININ; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; COMPLEMENT COMPONENT C1Q; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECALLANTIDE; ICATIBANT; TRANEXAMIC ACID;

ALLERGY; ANGIONEUROTIC EDEMA; BLOOD PRESSURE; BLOOD VESSEL PERMEABILITY; EDEMA; HUMAN; HYPERTHERMIA; INFLAMMATION; KALLIKREIN KININ SYSTEM; MEDICAL RESEARCH; NONHUMAN; PAIN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYMPTOM; VASODILATATION;

ANGIOEDEMA; ANIMALS; BIOMEDICAL RESEARCH; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; HUMANS; MICE; VASODILATOR AGENTS;

EID: 84860389162     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/j.1398-9995.2011.02686.x     Document Type: Review

References (83)

1. Kaplan AP, Joseph K, Silverberg M,. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol 2002; 109: 195-209. (Pubitemid 34158283)
2. Nussberger J, Cugno M, Cicardi M, Agostoni A,. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999; 104: 1321-1322. (Pubitemid 30004997)
3. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A,. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 2005; 99: 6-38. (Pubitemid 41366887)
4. Regoli D, Barabe J,. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980; 32: 1-46.
5. 2 receptor in the maturation of blood pressure phenotype: lesson from transgenic and knockout mice. Immunopharmacology 1999; 44: 9-13.
6. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE 3rd,. Increased vascular permeability in C1 inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109: 1057-1063. (Pubitemid 34408580)
7. Heitsch H,. Bradykinin B2 receptor as a potential therapeutic target. Drug News Perspect 2000; 13: 213-225.
8. Skidgel RA, Erdös EG,. Histamine, bradykinin and their antagonists. In:, Hardman JG, Limbird LE, Gilman AG, editors. The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill, 2006: 629-651.
9. Marceau F, Regoli D,. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004; 3: 845-852. (Pubitemid 39405945)
10. Kaplan AP, Ghebrehiwet B,. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol 2010; 47: 2161-2169.
11. Joseph K, Tholanikunnel BG, Kaplan AP,. Heat shock protein 90 catalyzes activation of the Prekallikrein-Kininogen Complex in the absence of factor XII. Proc Natl Acad Sci USA 2002; 99: 896-900. (Pubitemid 34106607)
12. Silverberg M, Dunn JT, Garen L, Kaplan AP,. Autoactivation of human Hageman factor: demonstration utilising a synthetic substrate. J Biol Chem 1980; 255: 7281-7286. (Pubitemid 11245061)
13. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL,. International Union of Pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005; 57: 27-77. (Pubitemid 40283969)
14. 2 bradykinin receptors is adjacent to and discriminates between the C-terminal residues of subtype-selective ligands. J Biol Chem 1998; 273: 12210-12218. (Pubitemid 28240585)
15. Leeb-Lundberg LM, Kang DS, Lamb ME, Fathy DB,. The human B1 bradykinin receptor exhibits high ligand-independent, constitutive activity. Roles of residues in the fourth intracellular and third transmembrane domains. J Biol Chem 2001; 276: 8785-8792.
16. 2 receptor endocytosis and delay constitutive B1 receptor endocytosis. Mol Pharmacol 2007; 71: 494-507. (Pubitemid 46147916)
17. 2+signaling in single cultured vascular smooth muscle cells. Mol Pharmacol 1996; 50: 128-139. (Pubitemid 26250084)
18. 2 receptor in vivo phosphorylation sites and their role in receptor function. J Biol Chem 2001; 276: 40431-40440.
19. Marceau F, Hess JF, Bachvarov DR,. The B1 receptors for kinins. Pharmacol Rev 1998; 50: 357-386.
20. Cayla C, Todiras M, Iliescu R, Saul VV, Gross V, Pilz B, et al., Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J 2007; 21: 1689-1698. (Pubitemid 46855614)
21. Silva JA Jr, Araujo RC, Baltatu O, Oliveira SM, Tschöpe C, Fink E, et al., Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. FASEB J 2000; 14: 1858-1860.
22. 2 receptors reduces arrhythmias in a rat model of cardiac hypertrophy. Hypertension 2009; 54: E54.
23. Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA Jr, Walther T, et al., Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc Natl Acad Sci USA 2000; 97: 8140-8145. (Pubitemid 30460786)
24. Merino VF, Todiras M, Campos LA, Saul V, Popova E, Baltatu OC, et al., Increased susceptibility to endotoxic shock in transgenic rats with endothelial overexpression of kinin B(1) receptors. J Mol Med 2008; 86: 791-798.
25. 1 receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J Immunol 2004; 172: 2542-2548. (Pubitemid 38182405)
26. 2 receptor activation reduces renal fibrosis. J Clin Invest 2002; 110: 371-379. (Pubitemid 34847969)
27. Klein J, Gonzalez J, Duchene J, Esposito L, Pradère JP, Neau E, et al., Delayed blockade of the kinin B1 receptor reduces renal inflammation and fibrosis in obstructive nephropathy. FASEB J 2009; 23: 134-142.
28. Mori MA, Araújo RC, Reis FC, Sgai DG, Fonseca RG, Barros CC, et al., Kinin B1 receptor deficiency leads to leptin hypersensitivity and resistance to obesity. Diabetes 2008; 57: 1491-1500.
29. Emanueli C, Bonaria Salis M, Stacca T, Pintus G, Kirchmair R, Isner JM, et al., Targeting kinin B(1) receptor for therapeutic neovascularization. Circulation 2002; 105: 360-366. (Pubitemid 34106186)
30. Bader M,. Kallikrein-kinin system in neovascularization. Arterioscler Thromb Vasc Biol 2009; 29: 617-619.
31. Merino VF, Todiras M, Mori MA, Sales VM, Fonseca RG, Saul V, et al., Predisposition to atherosclerosis and aortic aneurysms in mice deficient in kinin B1 receptor and apolipoprotein E. J Mol Med 2009; 87: 953-963.
32. Schulze-Topphoff U, Prat A, Prozorovski T, Siffrin V, Paterka M, Herz J, et al., Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 2009; 15: 788-793.
33. Raslan F, Schwarz T, Meuth SG, Austinat M, Bader M, Renné T, et al., Inhibition of bradykinin receptor B1 protects mice from focal brain injury by reducing blood-brain barrier leakage and inflammation. J Cereb Blood Flow Metab 2010; 30: 1477-1486.
34. Trabold R, Erös C, Zweckberger K, Relton J, Beck H, Nussberger J, et al., The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice. J Cereb Blood Flow Metab 2010; 30: 130-139.
35. 2+ exchanger. J Neurosci 2007; 27: 13065-13073. (Pubitemid 350220478)
36. Pocock JM, Kettenmann H,. Neurotransmitter receptors on microglia. Trends Neurosci 2007; 30: 527-535. (Pubitemid 47513237)
37. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, et al., Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363: 532-541.
38. Mehta D, Malik AB,. Signaling mechanisms regulating endothelial permeability. Physiol Rev 2006; 86: 279-367.
39. Nussberger J, Cugno M, Cicardi M,. Bradykinin-mediated angioedema. N Engl J Med 2002; 347: 621-622.
40. Arvidsson P, Löfdahl CG, Skoogh BE, Lötvall J,. Exudation of plasma and production of thromboxane in human bronchi after local bradykinin challenge. Respir Med 2001; 95: 313-318. (Pubitemid 32624473)
41. Lötvall JO, Tokuyama K, Barnes PJ, Chung KF,. Bradykinin-induced airway microvascular leakage is potentiated by captopril and phosphoramidon. Eur J Pharmacol 1991; 200: 211-217.
42. Cui ZH, Arakawa H, Kawikova I, Skoogh BE, Lötvall J,. Relationship between systemic blood pressure, airway blood flow and plasma exudation in guinea-pig. Acta Physiol Scand 1999; 165: 121-127. (Pubitemid 29090259)
43. Fields T, Ghebrehiwet B, Kaplan AP,. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation for C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol 1983; 72: 54-60. (Pubitemid 13069361)
44. Bossi F, Fischetti F, Regoli D, Durigutto P, Frossi B, Gobeil F Jr, et al., Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 2009; 124: 1303-1310.
45. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A,. Plasma bradykinin in angio-oedema. Lancet 1998; 351: 1693-1697. (Pubitemid 28254530)
46. Cugno M, Zanichelli A, Foieni F, Caccia S, Cicardi M,. C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med 2009; 15: 69-78.
47. Pappalardo E, Caccia S, Suffritti C, Tordai A, Zingale LC, Cicardi M,. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol 2008; 45: 3536-3544.
48. Donaldson VH, Rosen FS, Bing DH,. Role of the second component of complement (C2) and plasmin in kinin release in hereditary angioneurotic edema (H.A.N.E.) plasma. Trans Assoc Am Physicians 1977; 90: 174-183.
49. Davis AE 3rd,. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6: 595-628.
50. Cugno M, Zanichelli A, Bellatorre AG, Griffini S, Cicardi M,. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy 2009; 64: 254-257.
51. Kim JS, Pongracic JA,. Hereditary and acquired angioedema. Allergy Asthma Proc 2004; 25: S47-S49.
52. Cugno M, Castelli R, Cicardi M,. Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. Autoimmun Rev 2008; 8: 156-159.
53. Agostoni A, Aygören-Pürsün E, Binkley KE, Blanch A, Bork K, Bouillet L, et al., Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114: S51-S131. (Pubitemid 39200689)
54. Sánchez-Cano D, Callejas-Rubio JL, Lara-Jiménez MA, López-Trascasa M, Cicardi M, Ortego-Centeno N,. Successful use of rituximab in acquired C1 inhibitor deficiency secondary to Sjogren's syndrome. Lupus 2008; 17: 228-229. (Pubitemid 351588947)
55. Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T,. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007; 120: 416-422. (Pubitemid 47102386)
56. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W,. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007; 119: 1497-1503. (Pubitemid 46855846)
57. Weller K, Magerl M, Maurer M,. Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. J Eur Acad Dermatol Venereol 2011; 25: 119-120.
58. Bas M, Hoffmann TK, Bier H, Kojda G,. Increased C-reactive protein in ACE-inhibitor-induced angioedema. Br J Clin Pharmacol 2005; 59: 233-238. (Pubitemid 40208861)
59. Bas M, Hoffmann TK, Kojda G, Bier H,. ACE-inhibitor induced angioedema. Laryngorhinootologie 2007; 86: 804-808.
60. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G,. Nonallergic angioedema: role of bradykinin. Allergy 2007; 62: 842-856. (Pubitemid 47037860)
61. Duan QL, Nikpoor B, Dube MP, Molinaro G, Meijer IA, Dion P, et al., A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet 2005; 77: 617-626. (Pubitemid 41361608)
62. Bas M, Kirchhartz N, Hochfeld J, Tüllmann C, Kumpf S, Suvorava T, et al., Potential role of vasomotor effects of fibrinogen in bradykinin-induced angioedema. J Allergy Clin Immunol 2008; 121: 969.e2-975.e2.
63. Bas M, Hoffmann TK, Tiemann B, Dao VT, Bantis C, Balz V, et al., Potential genetic risk factors in angiotensin-converting enzyme-inhibitor- induced angio-oedema. Br J Clin Pharmacol 2010; 69: 179-186.
64. Bas M, Greve J, Stelter K, Bier H, Stark T, Hoffmann TK, et al., Therapeutic efficacy of icatibant in angioedema induced by angiotensin- converting enzyme inhibitors: a case series. Ann Emerg Med 2010; 56: 278-282.
65. Zingale LC, Beltrami L, Zanichelli A, Maggioni L, Pappalardo E, Cicardi B, et al., Angioedema without urticaria: a large clinical survey. CMAJ 2006; 24: 175.
66. Cugno M, Nussberger J, Cicardi M, Agostoni A,. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003; 3: 311-317. (Pubitemid 36293959)
67. Cicardi M, Bergamaschini L, Zingale LC, Gioffré D, Agostoni A,. Idiopathic nonhistaminergic angioedema. Am J Med 1999; 106: 650-654. (Pubitemid 29279302)
68. Cugno M, Cicardi M, Bottasso B, Coppola R, Paonessa R, Mannucci PM, et al., Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997; 89: 3213-3218.
69. Rajakulasingam K, Polosa R, Lau LC, Church MK, Holgate ST, Howarth PH,. Comparative nasal effects of bradykinin and histamine: influence on nasal airways resistance and plasma protein exudation. Thorax 1993; 48: 324-329. (Pubitemid 23126296)
70. Proud D, Togias A, Naclerio RM, Crush SA, Norman PS, Lichtenstein LM,. Kinins are generated in vivo following nasal airway challenge of allergic individuals with allergen. J Clin Invest 1983; 72: 1678-1685. (Pubitemid 14229047)
71. Naclerio RM, Proud D, Kagey-Sobotka A, Freidhoff L, Norman PS, Lichtenstein LM,. The effect of cetirizine on early allergic response. Laryngoscope 1989; 99: 596-599. (Pubitemid 19155263)
72. 2 receptors in human nasal mucosa. Mediators Inflamm 2009; 2009: 102406.
73. Christiansen SC, Eddleston J, Woessner KM, Chambers SS, Ye R, Pan ZK, et al., Up-regulation of functional kinin B1 receptors in allergic airway inflammation. J Immunol 2002; 169: 2054-2060. (Pubitemid 34857670)
74. 2 receptor antagonist, abolishes the hyper-responsiveness and nasal eosinophilia induced by antigen. J Allergy Clin Immunol 2001; 107: 105-113. (Pubitemid 32105253)
75. Eddleston J, Christiansen SC, Jenkins GR, Koziol JA, Zuraw BL,. Bradykinin increases the in vivo expression of the CXC chemokine receptors CXCR1 and CXCR2 in patients with allergic rhinitis. J Allergy Clin Immunol 2003; 111: 106-112. (Pubitemid 36143299)
76. Cugno M, Nussberger J, Biglioli P, Alamanni F, Coppola R, Agostoni A,. Increase of bradykinin in plasma of patients undergoing cardiopulmonary bypass: the importance of lung exclusion. Chest 2001; 120: 1776-1782. (Pubitemid 34053433)
77. Cugno M, Agostoni P, Mari D, Meroni PL, Gregorini L, Bussotti M, et al., Impaired bradykinin response to ischaemia and exercise in patients with mild congestive heart failure during angiotensin-converting enzyme treatment. Relationships with endothelial function, coagulation and inflammation. Br J Haematol 2005; 130: 113-120. (Pubitemid 40979142)
78. Cugno M, Agostoni P, Brunner HR, Gardinali M, Agostoni A, Nussberger J,. Plasma bradykinin levels in human chronic congestive heart failure. Clin Sci (Lond) 2000; 99: 461-466.
79. Merlini PA, Cugno M, Rossi ML, Agricola P, Repetto A, Fetiveau R, et al., Activation of the contact system and inflammation after thrombolytic therapy in patients with acute myocardial infarction. Am J Cardiol 2004; 93: 822-825. (Pubitemid 38429590)
80. Cugno M, Salerno F, Nussberger J, Bottasso B, Lorenzano E, Agostoni A,. Bradykinin in the ascitic fluid of patients with liver cirrhosis. Clin Sci (Lond) 2001; 101: 651-657. (Pubitemid 33135347)
81. Bas M, Kojda G,. Das nicht-allergische Angioödem. Fortbildungstelegramm Pharmazie 2008; 2: 85-100.
82. Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, et al., Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 2007; 13: 181-188.
83. Kocgirli O, Valcaccia S, Dao VT, Suvorava T, Kumpf S, Floeren M, et al., Effects of NO on endothelial vascular bradykinin type-2 receptor. EuroPRevent 2010 (European Society of Cardiology), Abstract P155.